Bangladesh has so far received over 1.6 million vials of the vaccine from Japan

After the audit of essential archives, the antibody got freedom from the BMRC, said Dr. Modasser.

He, notwithstanding, said the endorsement of the Directorate General of Drug Administration (DGDA) will be expected to begin the clinical preliminaries of Covaxin in the country.

India has intended to work with its clinical preliminaries in Bangladesh in a bid to improve the acknowledgment of native Covid antibody, Covaxin, as per Indian media reports.

India has not provided any Covaxin portions to Bangladesh up until now.

The first vaccine shipment from Japan containing 245,200 doses of the vaccine developed by AstraZeneca, in collaboration with Oxford, reached Bangladesh on July 24, while the second one, comprising 781,320 vials, arrived in Dhaka on Saturday.

Bangladesh launched its mass inoculation drive by using Covishield — the AstraZeneca Covid-19 vaccine manufactured by the Serum Institute of India — in February.

However, some 1.5 million people were left hanging for the second dose of the vaccine after the stock of the jabs purchased from India ran out.

The dispensation of the second dose of the vaccine was later continued, albeit only in the Dhaka division for now, on Monday.

By admin